Bronchiectasis, Non-Cystic FibrosisNCT07805174
High-Intensity Interval Exercise in Bronchiectasis Patients
A study testing high-intensity interval exercise and Airway clearance tecniques in people with Bronchiectasis, Non-Cystic Fibrosis and High Intensity Interval Exercise, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
Trial summary
The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are: 1. Does HIIE improve respiratory function in patients with bronchiectasis? 2. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Bronchiectasis, Non-Cystic Fibrosis, High Intensity Interval Exercise
- What is being tested?
- high-intensity interval exercise and Airway clearance tecniques
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 27 Mar 2026to 29 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Being over 18 years of age
- Having a clinical and radiological diagnosis of non-cystic fibrosis bronchiectasis
- Absence of cognitive impairment (MMT>24)
- Being clinically stable (not having experienced any exacerbation in the last 4 weeks)
Who cannot join
- Presence of any disease that may affect compliance with exercise (Unstable angina (within the last month), recent myocardial infarction (heart attack), uncontrolled arrhythmias, severe aortic stenosis, decompensated heart failure, severe pulmonary hypertension, acute respiratory tract infection, severe hypoxemia at rest (<85%), orthopedic or neurological problems that impede walking, severe anemia, acute infections, very high resting blood pressure (systolic >180-200 mmHg, diastolic >100-110 mmHg), psychological issues, etc.)
- Smoking
- Chronic alcoholism that may affect exercise safety (More than 1 drink per day on average for women, more than 2 drinks per day on average for men (1 standard drink ≈ 10-14 g of alcohol)
- Presence of any respiratory tract disease other than bronchiectasis
- After incremental shuttle walk test arterial oxygen saturation <80%
- Participation in a structured exercise program within the last 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Gulhane Faculty of Physiotherapy and Rehabilitation
Ankara, Keçiören, 06018
0 312 567 15 00, bilgiedinme@sbu.edu.tr
About this study
Official title: Investigation of the Effectiveness of High-Intensity Interval Exercise in Bronchiectasis Patients
The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are:
- Does HIIE improve respiratory function in patients with bronchiectasis?
- Does HIIE increase functional capacity, peripheral muscle strength, and quality of life in patients with bronchiectasis?
- Does HIIE reduce the severity of dyspnea, cough symptoms, and fatigue in patients with bronchiectasis?
Read more
The study was designed as a randomized controlled trial. Participants were divided into two groups: intervention and control.
Participants will:
The intervention group will receive HIIE training three days a week along with airway clearance techniques.
The control group would receive only airway clearance techniques. Airway clearance techniques will be provided clinically (three days a week) and at home, according to the needs of the individuals each day of the week.
- Being tested
- high-intensity interval exercise, Airway clearance tecniques
- Keywords
- Airway clearance techniques, high-intensity interval exercise
- Medical subject headings
- Bronchiectasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
high-intensity interval exerciseOther
The high-intensity interval exercise (HIIE) protocol (4×4 model: 4 minutes at 85-95% maximum heart rate, with 3 minutes of active recovery at 60-70% in between), will be applied 3 days a week for 8 weeks using a treadmill or cycle ergometer, taking into account the participants' physical characteristics and safety requirements.
Airway clearance tecniquesOther
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied. Additionally, the autogenic drainage technique will be taught to patients for them to practice at home. Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Active comparator | Patients in this group will perform airway clearance techniques along with high-intensity interval exercise. Receives: Other: high-intensity interval exercise; Other: Airway clearance tecniques |
| Control | Active comparator | Patients in this group will only undergo airway clearance techniques. Receives: Other: Airway clearance tecniques |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional Performance
Functional performance will be measured using an incremental shuttle walk test.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Secondary outcomes (9)
Maximal Inspiratory Pressure (PImax)
Inspiratory muscle strength will be assessed by measuring the maximal inspiratory pressure (PImax) using an electronic, portable, intraoral pressure measuring device. PImax represents the maximum negative pressure generated during a forceful inhalation against an occluded airway. Results will be reported in centimeters of water (cmH2O), with higher absolute values indicating greater inspiratory muscle strength.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Maximal Expiratory Pressure (PEmax)
Expiratory muscle strength will be assessed by measuring the maximal expiratory pressure (PEmax) using an electronic, portable, intraoral pressure measuring device. PEmax represents the maximum positive pressure generated during a forceful exhalation against an occluded airway. Results will be reported in centimeters of water (cmH2O), with higher values indicating greater expiratory muscle strength.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) is the total volume of air that can be exhaled forcefully and completely after a maximal inspiration. It is measured using spirometry to assess overall lung volume and capacity. The results will be reported as an absolute volume in Liters (L).
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
FEV1 (Forced Expiratory Volume in 1 Second)
Forced Expiratory Volume in 1 second (FEV1) is the volume of air forcefully exhaled during the first second after a maximal inspiration, measured using spirometry. Outcomes are reported in absolute volume (Liters) and % to evaluate airway obstruction and overall pulmonary function.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
FEV1/FVC
FEV1/FVC(%) will be calculated using the FEV1 and FVC values obtained from the pulmonary function test.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Fatigue
To assess the severity of fatigue and its impact on daily life, the Fatigue Severity Scale (FSS), a self-report scale, will be used. The scale consists of 9 items, each scored between 1 (strongly disagree) and 7 (strongly agree). The average score is calculated by dividing the total score by the number of items, with higher scores indicating more severe fatigue. A score of 4 or higher generally indicates severe fatigue.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Dyspnea Severity
Dyspnea severity will be assessed using the Modified Medical Research Council dyspnea scale. The scale classifies dyspnea on a five-point scale from 0 to 4; a score of 0 indicates dyspnea occurring only during strenuous exercise, while a score of 4 describes significant shortness of breath even during the mildest daily activities.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
The Bronchiectasis Health Questionnaire
The Bronchiectasis Health Questionnaire (BHQ) will be used to assess disease-specific quality of life. The BHQ is a patient-completed scale consisting of 10 items that evaluates symptom burden, physical function, and the impact of the disease on daily life. Each item is scored between 0 and 7, and the total score ranges from 0 to 70; higher scores indicate better health status and quality of life.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Cough Questionnaire
The Leicester Cough Questionnaire (LCQ) is a disease-specific, patient-completed scale developed to assess the impact of cough on quality of life in individuals with chronic cough. The LLC consists of 19 items and covers three sub-dimensions: physical, psychological, and social. Each item is scored between 1 and 7, and the average of the sub-dimension scores is calculated and summed to obtain a total score ranging from 3 to 21; higher scores indicate better quality of life and less cough-related impact.
Measured: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2026
- Study start27 Mar 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion29 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bronchiectasis, Non-Cystic FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 42 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Saglik Bilimleri Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07805174
- Sponsor's protocol ID
- 2026-085
- Status last verified
- Apr 2026
- First submitted
- 21 Apr 2026
- Last updated
- 4 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Due to patient confidentiality, data will not be shared.
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Effectiveness of High-Intensity Interval Exercise in Bronchiectasis Patients
- ClinicalTrials.gov ID
- NCT07805174
- Acronym / sponsor ID
- 2026-085
- Keywords
- Airway clearance techniques, high-intensity interval exercise
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 42 participants (estimated)
- Lead sponsor
- Saglik Bilimleri UniversitesiUniversity, hospital or other
- Study start
- 27 Mar 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 29 May 2027 (estimated)
- First posted
- 4 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are:
- Does HIIE improve respiratory function in patients with bronchiectasis?
- Does HIIE increase functional capacity, peripheral muscle strength, and quality of life in patients with bronchiectasis?
- Does HIIE reduce the severity of dyspnea, cough symptoms, and fatigue in patients with bronchiectasis?
The study was designed as a randomized controlled trial. Participants were divided into two groups: intervention and control.
Participants will:
The intervention group will receive HIIE training three days a week along with airway clearance techniques.
The control group would receive only airway clearance techniques. Airway clearance techniques will be provided clinically (three days a week) and at home, according to the needs of the individuals each day of the week.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Active comparator | Other: high-intensity interval exercise, Other: Airway clearance tecniquesPatients in this group will perform airway clearance techniques along with high-intensity interval exercise. |
| Control | Active comparator | Other: Airway clearance tecniquesPatients in this group will only undergo airway clearance techniques. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Being over 18 years of age
- Having a clinical and radiological diagnosis of non-cystic fibrosis bronchiectasis
- Absence of cognitive impairment (MMT>24)
- Being clinically stable (not having experienced any exacerbation in the last 4 weeks)
Key exclusion criteria (6 listed)
- Presence of any disease that may affect compliance with exercise (Unstable angina (within the last month), recent myocardial infarction (heart attack), uncontrolled arrhythmias, severe aortic stenosis, decompensated heart failure, severe pulmonary hypertension, acute respiratory tract infection, severe hypoxemia at rest (<85%), orthopedic or neurological problems that impede walking, severe anemia, acute infections, very high resting blood pressure (systolic >180-200 mmHg, diastolic >100-110 mmHg), psychological issues, etc.)
- Smoking
- Chronic alcoholism that may affect exercise safety (More than 1 drink per day on average for women, more than 2 drinks per day on average for men (1 standard drink ≈ 10-14 g of alcohol)
- Presence of any respiratory tract disease other than bronchiectasis
- After incremental shuttle walk test arterial oxygen saturation <80%
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| high-intensity interval exerciseThe high-intensity interval exercise (HIIE) protocol (4×4 model: 4 minutes at 85-95% maximum heart rate, with 3 minutes of active recovery at 60-70% in between), will be applied 3 days a week for 8 weeks using a treadmill or cycle ergometer, taking into account the participants' physical characteristics and safety requirements. | Other | Intervention |
| Airway clearance tecniquesAmong the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied. Additionally, the autogenic drainage technique will be taught to patients for them to practice at home. Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed. | Other | Control, Intervention |
Primary outcome
Functional Performance
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Functional performance will be measured using an incremental shuttle walk test.
9 secondary outcomes
Maximal Inspiratory Pressure (PImax)
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Maximal Expiratory Pressure (PEmax)
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Forced Vital Capacity (FVC)
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
FEV1 (Forced Expiratory Volume in 1 Second)
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
FEV1/FVC
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Fatigue
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Dyspnea Severity
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
The Bronchiectasis Health Questionnaire
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
Cough Questionnaire
Time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: No. Due to patient confidentiality, data will not be shared.
Related trials for Bronchiectasis, Non-Cystic Fibrosis
RecruitingPhase 3
Compare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations
Bronchiectasis, Bronchiectasis Adult
Active, not recruitingObservational study
Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis
RecruitingPhase 2
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Non-cystic Fibrosis Bronchiectasis
Active, not recruitingPhase 1
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
RecruitingObservational study
Regional Phenotyping of CF and Non-CF Bronchiectasis
Cystic Fibrosis, Non-CF Bronchiectasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing high-intensity interval exercise and Airway clearance tecniques in people with Bronchiectasis, Non-Cystic Fibrosis and High Intensity Interval Exercise, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mustafa Ertuğrul YAŞA, Associate Professor (0312 304 61 97, mustafaertugrul.yasa@sbu.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional Performance (time frame: At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.